Company Description
Baxter Healthcare Corporation's BioPharma Solutions business offers proprietary technologies and contract services, addressing
outsourcing needs throughout development and commercialization of parenteral (injectable and pulmonary) drugs. The company
has partnered with more than 150 clients, working with the top 15 biopharmaceutical companies.
Products and Services
Contract Services: Baxter provides a range of contract services from process development of biopharmaceutical active ingredients
to form–fill–finish of drug product into syringes, vials, and cartridges. It also provides cytotoxic contract services from
chemical synthesis (API) to scale-up for commercial production. With over 15 years of experience, we provide contract development
and manufacturing services for antibodies and protein therapeutics. Our licensed facilities in Hayward and Thousand Oaks,
California, have capacity for preclinical to commercial scale production.
Baxter's Bloomington facility has expanded capacities for syringe and vial filling–finishing; and has added new capability
in cartridge filling–finishing as well as a fully automated kitting line. Lyophilization capacity has increased along with
the establishment of the Lyophilization Center of Excellence. Baxter can also provide analytical and microbiological services
as well as validation and regulatory assistance.
Proprietary Formulation Technologies: NANOEDGE dispersion technology offers innovative formulations for solubility challenges
and is applicable to multiple routes of administration. It reduces the particle size of most drugs to nanometer size, which
can enhance a drug's saturation solubility and dissolution rate. It also eliminates the need for undesirable cosolvents and
can offer higher drug loading and subsequent lower dose volume.
The PROMAXX microsphere technology is a unique, elegant, and cost effective formulation platform, tailored to fit specific
requirements. It is applicable to a broad range of molecules— from small molecules and nucleic acids to peptides and proteins.
PROMAXX technology can offer high drug loading and precise particle-size control and enable dosing flexibility across various
administration routes, such as injectable and pulmonary with various drug release profiles such as immediate- and sustained-release.
Enhanced Packaging: Baxter also offers ready-to-use and ready-to-mix systems that can help differentiate your molecule and
simplify end-users' drug preparation and administration. An established franchise into critical care clinicians globally supports
end-user acceptance and market presence.
BAXTER HEALTHCARE CORPORATION
PO Box 3068
927 S. Curry Pike
Bloomington, IN 47403
TELEPHONE
800.353.0887
812.333.0887
FAX
812.332.3079
EMAIL
busdev@baxter.com
WEB ADDRESS
http://www.baxterdrugdelivery.com/
EMPLOYEES
600
FOUNDED
1991
